Dual antiplatelet therapy effective: MASTER DAPT Trial

Fatal heart diseases are most commonly caused by formation of clots in major blood vessels,  its a serious risk that needs to be managed immediately. Antiplatelet medicines can stop blood clots from forming. Anticoagulant therapy has established its place in reducing systemic thrombotic events in patients with atrial fibrillation. Efficacy of anticoagulant therapy has established its place in reducing systemic thrombotic events in patients with atrial fibrillation.

 Abbreviated antiplatelet therapy was non-inferior to standard antiplatelet therapy with regard to net adverse clinical events reveals the MASTER DAPT trial. The trial evaluated abbreviated antiplatelet therapy compared with standard antiplatelet therapy among patients who underwent percutaneous coronary intervention (PCI) with a biodegradable-polymer sirolimus-eluting stent.